4/A: Cumberland Pharmaceuticals Director Amends Filing to Correct Share Acquisition

A Cumberland Pharmaceuticals director amended a previous filing to correct the number of shares acquired, increasing the reported amount by 1,500 shares.

Summary

• This document is an amended SEC Form 4 filing by Kenneth Krogulski, a director at Cumberland Pharmaceuticals.
• The amendment corrects an error in the original filing from March 26, 2024, regarding the number of shares acquired on March 25, 2024.
• The original filing incorrectly stated that 1,000 shares were acquired, but the correct number is 2,500 shares.
• This amendment reflects an increase of 1,500 shares acquired by the director.
• Following the corrected transaction, Mr. Krogulski beneficially owns 277,843 shares of Cumberland Pharmaceuticals common stock.

Sentiment

Score: 7

Explanation: The document is a routine correction of a previous filing, indicating no significant positive or negative sentiment. The correction is a normal part of regulatory compliance.

Industry Context

This is a routine filing related to insider trading activity and is common for publicly traded companies. It does not indicate any specific trend in the pharmaceutical industry.

Comparison to Industry Standards

• SEC Form 4 filings are standard practice for all publicly traded companies in the US.
• The filing is similar to those of other directors and officers at comparable companies such as Amarin Corporation and Pacira BioSciences, who also regularly report changes in their beneficial ownership.
• The amendment is not unusual, as administrative errors can occur and are typically corrected promptly.

Stakeholder Impact

• The correction of the filing ensures transparency for shareholders regarding insider transactions.
• The impact on other stakeholders is minimal as this is a routine administrative correction.

Key Dates

Keywords

SEC Form 4, Beneficial Ownership, Cumberland Pharmaceuticals, Director, Share Acquisition, Amendment, Kenneth Krogulski